300972 Stock Overview
Fujian Wanchen Biotechnology Co., Ltd engages in the research and development, cultivation, production, and sale of edible fungi in China.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Fujian Wanchen Biotechnology Group Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥23.37 |
52 Week High | CN¥46.99 |
52 Week Low | CN¥22.20 |
Beta | 0.064 |
1 Month Change | -17.48% |
3 Month Change | -27.44% |
1 Year Change | -45.89% |
3 Year Change | 28.05% |
5 Year Change | n/a |
Change since IPO | -14.40% |
Recent News & Updates
Shareholder Returns
300972 | CN Food | CN Market | |
---|---|---|---|
7D | -7.2% | -2.5% | -2.3% |
1Y | -45.9% | -13.9% | -13.6% |
Return vs Industry: 300972 underperformed the CN Food industry which returned -13.9% over the past year.
Return vs Market: 300972 underperformed the CN Market which returned -13.6% over the past year.
Price Volatility
300972 volatility | |
---|---|
300972 Average Weekly Movement | 6.4% |
Food Industry Average Movement | 5.7% |
Market Average Movement | 6.8% |
10% most volatile stocks in CN Market | 10.1% |
10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 300972's share price has been volatile over the past 3 months.
Volatility Over Time: 300972's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 4,972 | Li Qing Wang | www.vanchen.com |
Fujian Wanchen Biotechnology Co., Ltd engages in the research and development, cultivation, production, and sale of edible fungi in China. It offers flammulina velutipes; and crab-flavored, white jade, seafood mushrooms, etc. The company was founded in 2011 and is based in Zhangpu, China.
Fujian Wanchen Biotechnology Group Co., Ltd. Fundamentals Summary
300972 fundamental statistics | |
---|---|
Market cap | CN¥4.03b |
Earnings (TTM) | -CN¥129.32m |
Revenue (TTM) | CN¥13.36b |
0.3x
P/S Ratio-31.2x
P/E RatioIs 300972 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
300972 income statement (TTM) | |
---|---|
Revenue | CN¥13.36b |
Cost of Revenue | CN¥12.15b |
Gross Profit | CN¥1.21b |
Other Expenses | CN¥1.34b |
Earnings | -CN¥129.32m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.75 |
Gross Margin | 9.04% |
Net Profit Margin | -0.97% |
Debt/Equity Ratio | 95.9% |
How did 300972 perform over the long term?
See historical performance and comparison